Better than expected non-US sales, even to the point of reaching the 20M estimate by year end in spite of slow US sales should put to rest any concerns about the drug itself IMO.
>Do you guys consider there is some inflection point at which it could be said that sales are definitely not going to take off and Tyzeka will be a commercial failure?<
Sure, but we’re not close to that point yet, IMO. Here’s another look at Baraclude’s early sales so you can see what I mean: #msg-21567340.
Market Data 
Markets 
AI
